

**> PRESS RELEASE/ 31 October 2013**

---

**Coloplast delivers record results and raises expectations for revenue and earnings**

*Revenue was up by 7% to DKK 11,635m for the 2012/13 financial year with the EBIT margin at 32% versus 30% last year. EBIT increased by 13% to DKK 3,672m.*

"I'm very pleased with our strong full-year financial results. We lifted both our sales growth and our EBIT margin to the upper end of our guidance range. With our healthy growth performance in all business areas and in all regions during the past financial year, we have consolidated our position as a global market leader," says Coloplast's CEO Lars Rasmussen.

Sales growth by business area was as follows: Ostomy Care 7%, Continence Care 7%, Urology Care 9% and Wound & Skin Care 5%. Revenue increased by 5% in Europe, by 9% in other developed markets and by 14% in other markets.

"These are excellent results. We grew our business by 7% overall in a market that is growing by 4–5%. We're beginning to see the results of the investments in growth we announced in 2012, and we expect this strong growth to continue into next year," Lars Rasmussen adds.

For the 2013/2014 financial year, Coloplast projects revenue growth of about 7% and an EBIT margin of around 33%, both at constant exchange rates and in DKK.

**Distributor agreement for the Wound Care business based on innovative technology**

Together with the release of the full-year financial report, Coloplast is announcing a new distributor agreement with the US-based medtech company Devon Medical International.

The agreement gives Coloplast exclusive rights to distribute Devon's already approved product portfolio for Negative Pressure Wound Therapy (NPWT) in the EU, Brazil, China and other markets.

"Our Wound Care business has grown for three straight quarters, and we've now completed the turnaround we initiated a few years back. The deal with Devon is a natural next step in achieving our ambition for sustained growth in this business area," says Lars Rasmussen.

For further information, click [here](#) to read the Full Year Financial Report for 2012/2013.

---

The Coloplast Annual Report for 2012/13 will be released later today. For more information, go to <http://www.coloplast.dk/omcoloplast/investorrelations/arsrapporter/>.

Also later today, Coloplast will release its Corporate Responsibility Report for 2012/13. For more information, go to <http://www.coloplast.com/about/responsibility/>.

**PRESS CONTACT**

Ulla Lundhus  
 Head of Media and Positioning  
 +45 4911 1929  
[dkul@coloplast.com](mailto:dkul@coloplast.com)

Simon Mehl Augustesen  
 Media Relations Manager  
 +45 4911 3488  
[dksia@coloplast.com](mailto:dksia@coloplast.com)

**INVESTOR RELATIONS**

Ian Christensen  
 Vice President, Investor Relations  
 +45 4911 1301  
[dkisec@coloplast.com](mailto:dkisec@coloplast.com)

Financial highlights and key ratios DKKm	2012/13	2011/12	Change	Q4 2012/13	Q4 2011/12	Change
Revenue	11,635	11,023	6%	2,970	2,849	4%
EBIT	3,672	3,255	13%	973	891	9%
EBIT margin	32%	30%	2 p.p.	33%	31%	2 p.p.

Sales performance by business area	DKKm 2012/13 12 mths.	DKKm 2011/12 12 mths.	Organic growth	Reported growth	DKKm 2012/13 Q4	Organic growth Q4
Ostomy Care	4,849	4,633	7%	5%	1,237	7%
Continence Care	4,081	3,831	7%	7%	1,051	11%
Urology Care	1,124	1,037	9%	8%	280	10%
Wound & Skin Care	1,581	1,522	5%	4%	402	7%
<b>Revenue</b>	<b>11,635</b>	<b>11,023</b>	<b>7%</b>	<b>6%</b>	<b>2,970</b>	<b>9%</b>